Open Access

Erratum to: Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer

  • Andrea Prodosmo1,
  • Amelia Buffone4,
  • Manlio Mattioni1,
  • Agnese Barnabei3,
  • Agnese Persichetti3, 4,
  • Aurora De Leo3,
  • Marialuisa Appetecchia3,
  • Arianna Nicolussi11,
  • Anna Coppa11,
  • Salvatore Sciacchitano5,
  • Carolina Giordano6,
  • Paola Pinnarò6,
  • Giuseppe Sanguineti6,
  • Lidia Strigari7,
  • Gabriele Alessandrini8,
  • Francesco Facciolo8,
  • Maurizio Cosimelli9,
  • Gian Luca Grazi9,
  • Giacomo Corrado10,
  • Enrico Vizza10,
  • Giuseppe Giannini2, 4Email author and
  • Silvia Soddu1Email author
Journal of Experimental & Clinical Cancer Research201635:185

https://doi.org/10.1186/s13046-016-0459-z

Received: 14 November 2016

Accepted: 17 November 2016

Published: 28 November 2016

The original article was published in Journal of Experimental & Clinical Cancer Research 2016 35:135

Erratum

In original publication of this article [1], the data for “Pat#7” in Additional file 1 was listed as “c.4436+24G>A” in the “Nucleotide change” column. Instead, the number should have been c.4436+24A>G.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Unit of Cellular Networks and Molecular Therapeutic Targets, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute – IRCCS
(2)
Istituto Pasteur-Fondazione Cenci Bolognetti, Department of Molecular Medicine, University La Sapienza
(3)
Endocrinology Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS
(4)
Department of Molecular Medicine, University La Sapienza
(5)
Department of Clinical and Molecular Medicine, University La Sapienza, Laboratorio di Ricerca Biomedica, Fondazione Università Niccolò Cusano per la Ricerca Medico Scientifica
(6)
Radiotherapy Unit, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute - IRCCS
(7)
Medical Physics Unit, Department of Research, Advanced Diagnostic, and Technological Innovation, Regina Elena National Cancer Institute – IRCCS
(8)
Toracic Surgery Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS
(9)
Hepato-pancreato-biliary Surgery Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS
(10)
Gynecological Oncology Unit, Department of Clinical and Experimental Oncology, Regina Elena National Cancer Institute – IRCCS
(11)
Department of Experimental Medicine, Sapienza University of Rome

Reference

  1. Prodosmo A, et al. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. J Exp Clin Cancer Res. 2016;35:135. doi:10.1186/s13046-016-0410-3.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement